WW:NASDAQWW International, Inc. Analysis
Data as of 2026-05-11 - not real-time
$10.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
WW International is trading at $10.2, well below its 20‑day SMA of 10.37, 50‑day SMA of 14.80 and 200‑day SMA of 25.27, indicating a bearish price trend despite a modestly bullish MACD crossover (MACD line above signal) and an RSI around 42 that suggests no extreme overbought/oversold condition. Valuation metrics are strikingly low: a trailing P/E of 1.55 versus an industry average of 26.45, a price‑to‑book of 0.32 and analyst median target of $30 imply substantial upside potential, while the DCF‑derived fair value of $0.89 raises a question of model sensitivity. Fundamentally, the company faces challenges—revenue has contracted 11.7% YoY, operating margin is negative, and operating cash flow is -$28.9 M, yet gross margins remain healthy at 71.7% and free cash flow is positive at $23.8 M. The balance sheet is leveraged, with total debt of $468 M and a debt‑to‑equity ratio of 147%, but cash holdings of $160 M provide a modest cushion.
The stock exhibits extreme volatility (128% 30‑day) and a high beta of 2.13, signaling sensitivity to market swings, while liquidity is acceptable for a $102 M market‑cap company with rising volume. Given the mix of deep value indicators, operational headwinds, and a strategic shift toward digital subscriptions and GLP‑1‑related services, WW presents a nuanced risk‑reward profile that leans toward a longer‑term upside thesis despite short‑term technical weakness.
The stock exhibits extreme volatility (128% 30‑day) and a high beta of 2.13, signaling sensitivity to market swings, while liquidity is acceptable for a $102 M market‑cap company with rising volume. Given the mix of deep value indicators, operational headwinds, and a strategic shift toward digital subscriptions and GLP‑1‑related services, WW presents a nuanced risk‑reward profile that leans toward a longer‑term upside thesis despite short‑term technical weakness.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages signaling bearish momentum
- High volatility and beta increasing market‑risk exposure
- Bullish MACD histogram suggesting possible short‑term reversal
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Extremely low P/E and P/B relative to peers
- Analyst median price target of $30 indicating >180% upside
- Positive free cash flow and strong gross margins supporting profitability
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic shift to digital subscription and GLP‑1 medication services
- Undervalued balance‑sheet metrics despite high leverage
- Long‑term industry tailwinds in weight‑management and health‑tech
Key Metrics & Analysis
Financial Health
Revenue Growth-11.70%
Profit Margin148.60%
P/E Ratio1.6
ROA6.74%
Debt/Equity147.33
P/B Ratio0.3
Op. Cash Flow$-28897000
Free Cash Flow$23.8M
Industry P/E26.4
Technical Analysis
TrendBearish
RSI42.0
Support$8.36
Resistance$12.20
MA 20$10.37
MA 50$14.80
MA 200$25.27
MACDBullish
VolumeIncreasing
Fear & Greed Index90.73
Valuation
Fair Value$0.89
Target Price$28.33
Upside/Downside177.78%
GradeUndervalued
TypeValue
Risk Assessment
Beta2.13
Volatility128.20%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.